These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

314 related articles for article (PubMed ID: 26050944)

  • 1. [18F]Fluorodeoxyglucose PET in Thoracic Malignancies.
    Vilstrup MH; Torigian DA
    PET Clin; 2014 Oct; 9(4):391-420, v. PubMed ID: 26050944
    [TBL] [Abstract][Full Text] [Related]  

  • 2. PET: other thoracic malignancies.
    Quint LE
    Cancer Imaging; 2006 Oct; 6(Spec No A):S82-8. PubMed ID: 17114082
    [TBL] [Abstract][Full Text] [Related]  

  • 3. PET scan contribution in chest tumor management: a systematic review for thoracic surgeons.
    Duranti L; Leo F; Pastorino U
    Tumori; 2012; 98(2):175-84. PubMed ID: 22677982
    [TBL] [Abstract][Full Text] [Related]  

  • 4. ¹⁸F-FDG uptake on PET is a predictive marker of thymidylate synthase expression in patients with thoracic neoplasms.
    Kaira K; Yamamoto N; Endo M; Kenmotsu H; Naito T; Ono A; Murakami H; Ohde Y; Nakajima T; Takahashi T
    Oncol Rep; 2014 Jan; 31(1):209-15. PubMed ID: 24173608
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Malignant pleural mesothelioma: utility of 18 F-FDG PET.
    Spitilli MG; Treglia G; Calcagni ML; Giordano A
    Ann Ital Chir; 2007; 78(5):393-6. PubMed ID: 18338546
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Patterns of lymphadenopathy in thoracic malignancies.
    Sharma A; Fidias P; Hayman LA; Loomis SL; Taber KH; Aquino SL
    Radiographics; 2004; 24(2):419-34. PubMed ID: 15026591
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Value of FDG PET in the management of NSCLC.
    Ukena D; Hellwig D
    Lung Cancer; 2004 Aug; 45 Suppl 2():S75-8. PubMed ID: 15552785
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Impact of whole-body ¹⁸F-fluorodeoxyglucose positron emission tomography on therapeutic management of non-small cell lung cancer.
    Heo EY; Yang SC; Yoo CG; Han SK; Shim YS; Kim YW
    Respirology; 2010 Nov; 15(8):1174-8. PubMed ID: 20573060
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Present and future roles of FDG-PET/CT imaging in the management of malignant pleural mesothelioma.
    Kitajima K; Doi H; Kuribayashi K
    Jpn J Radiol; 2016 Aug; 34(8):537-47. PubMed ID: 27222020
    [TBL] [Abstract][Full Text] [Related]  

  • 10. ¹⁸F-FDG uptake on PET could be a predictive marker of excision repair cross-complementation group 1 (ERCC1) expression in patients with thoracic neoplasms?
    Kaira K; Endo M; Shukuya T; Kenmotsu H; Naito T; Ono A; Tsuya A; Nakamua Y; Takahashi T; Murakami H; Kondo H; Nakajima T; Yamamoto N
    Neoplasma; 2012; 59(3):257-63. PubMed ID: 22329847
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Clinical value of fluorodeoxyglucose-positron emission tomography/computed tomography in differentiation of malignant mesothelioma from asbestos-related benign pleural disease: an observational pilot study.
    Yildirim H; Metintas M; Entok E; Ak G; Ak I; Dundar E; Erginel S
    J Thorac Oncol; 2009 Dec; 4(12):1480-4. PubMed ID: 19875971
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Sarcomatoid carcinoma (carcinosarcoma) of the lung mimics malignant pleural mesothelioma on 18F-FDG PET/CT: a report of 2 cases.
    Ciarallo A; Makis W; Novales-Diaz JA; Lisbona R
    Clin Nucl Med; 2012 Apr; 37(4):416-9. PubMed ID: 22391723
    [No Abstract]   [Full Text] [Related]  

  • 13. Oncological applications of positron emission tomography for evaluation of the thorax.
    Kwee TC; Torigian DA; Alavi A
    J Thorac Imaging; 2013 Jan; 28(1):11-24. PubMed ID: 23249968
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Non-small cell lung cancer: evaluation of pleural abnormalities on CT scans with 18F FDG PET.
    Schaffler GJ; Wolf G; Schoellnast H; Groell R; Maier A; Smolle-Jüttner FM; Woltsche M; Fasching G; Nicoletti R; Aigner RM
    Radiology; 2004 Jun; 231(3):858-65. PubMed ID: 15105451
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [Current status of 18F-FDG PET in predicting outcome of cancer therapy].
    Gong HY; Yu JM
    Zhonghua Zhong Liu Za Zhi; 2004 Oct; 26(10):577-80. PubMed ID: 16429617
    [No Abstract]   [Full Text] [Related]  

  • 16. Positron Emission Tomography (PET) radiotracers in oncology--utility of 18F-Fluoro-deoxy-glucose (FDG)-PET in the management of patients with non-small-cell lung cancer (NSCLC).
    Miele E; Spinelli GP; Tomao F; Zullo A; De Marinis F; Pasciuti G; Rossi L; Zoratto F; Tomao S
    J Exp Clin Cancer Res; 2008 Oct; 27(1):52. PubMed ID: 18928537
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The utility of fluorodeoxyglucose positron emission tomography in the evaluation of carcinoid tumors presenting as pulmonary nodules.
    Daniels CE; Lowe VJ; Aubry MC; Allen MS; Jett JR
    Chest; 2007 Jan; 131(1):255-60. PubMed ID: 17218584
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Prognosis and reevaluation of lung cancer by positron emission tomography imaging.
    Erasmus JJ; Rohren E; Swisher SG
    Proc Am Thorac Soc; 2009 Apr; 6(2):171-9. PubMed ID: 19349485
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Does whole-body 2-[18F]-fluoro-2-deoxy-D-glucose positron emission tomography have an advantage over thoracic positron emission tomography for staging patients with lung cancer?
    Aquino SL; Fischman AJ
    Chest; 2004 Sep; 126(3):755-60. PubMed ID: 15364753
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Comparison of (11)C-choline and (18)F-FDG PET in primary diagnosis and staging of patients with thoracic cancer.
    Pieterman RM; Que TH; Elsinga PH; Pruim J; van Putten JW; Willemsen AT; Vaalburg W; Groen HJ
    J Nucl Med; 2002 Feb; 43(2):167-72. PubMed ID: 11850480
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 16.